Society of Nuclear Medicine and Molecular Imaging Nov 7 2025 A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to new research published in the November issue of  The Journal of Nuclear Medicine . The regimen, which pre-treats the tumor before delivering targeted alpha-radioimmunotherapy, resulted in durable major responses--including histologic cures--with minimal toxicities, paving the way for a safer